Huahai US Inc. was established in 2004 as the first Chinese pharmaceutical company to file an ANDA and our parent company was the 1st to receive FDA approval in 2007, Huahai US Inc. was the first to open the doors into the American generic market. In 2010, the company began to market generic finished dosage products through the subsidiary company, Prinston Pharmaceutical Inc., which has spun off from Zhejiang Huahai Pharmaceutical Co., Ltd in 2009. As the most important subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd, Huahai US Inc. successfully assisted the parent company to become the first Chinese pharmaceutical company awarded with a contract manufacturing project for a well-known brand name pharmaceutical company for an under-patent product. Currently, Huahai US Inc has 35 US DMFs and assisted Prinston Pharmaceutical Inc. to get over 15 ANDAs approved by FDA.
Today, Huahai US Inc. focuses on the marketing and sales for our internal APIs and looks forward to continually growing the business in the US and beyond.